Title: Efficacy and Safety of Intravenous Tranexamic Acid in Control of Bleeding in Total Knee Replacement - A Randomised Clinical Trial

Authors: Dr HariKumar A, Dr Sobha S

 DOI:  https://dx.doi.org/10.18535/jmscr/v5i3.176

Abstract

Background: Major orthopedic procedures including total knee replacement, hip replacement, and spine surgeries are associated with severe bleeding because of extensive dissection through bony and fibrotic tissue, increased fibrinolysis due to tourniquet application, surgery and inability to cauterize bleeding bony surfaces. This study aims on the efficacy and safety of tranexamic acid which is an antifibrinolytic agent that decreases total blood loss in the prevention of bleeding in total knee replacement.

Materials and Methods: This Randomised Double Blind Controlled Clinical Trial was conducted after obtaining approval of Research methodology and institutional ethics committee and written informed consent from all patients. Adult patients of ASA I and II Class, of age 30-60yrs, satisfying the selection criteria, undergoing elective TKR surgery were selected and randomly allocated into two groups, Group 1 TU: Unilateral TKR patients received tranexamic acid 10 mg/kg intravenously before the tourniquet applications followed by 1 mg/kg/hour till the end of the surgery and Group 2, CU: Unilateral TKR patients not received tranexamic  acid .Blood loss was measured in the post operative period after 4 hours and 24 hours.

Results: The two groups were comparable in terms of age, gender, preoperative Hb (gm/dl), PCV (%) and duration of surgery. A statistically significant reduction in blood loss by more than 65% was observed in patients who received tranexamic acid.

Conclusion: The observation of this study shows that tranexamic acid can significantly reduce perioperative blood loss without any side effects in patients undergoing total knee replacement.

Keywords: Total knee replacement, Tranexamic acid, Blood loss.

References

1.      Perka C. Arnold U, Butterzeit F: Influen-cing factors on Perioperative morbidity in knee arthroplasty clin Orthop 183:191-196-2000.

2.      .Zimmerman LH. Causes and consequences of critical bleeding and mechanisms of blood   coagulation.  Pharmacotherapy 2007;27(9 pt2):45S-56S

3.      HENRY DA,CARLESS PA McCLELL AND B et al  Cocharane database of systemic reviews 2007 Okamoto S, Sato S, Takada Y,

4.      Okamoto U.  An active stereo-isomer (transform) of AMCHA and its antifibrinolytic (antiplasminic) action in vitro.Keio J Med 1964;13:177-185.

5.      Tranexamic acid.  Drugdex drug evalu-ations:  Klasco RK (Editor): DRUGDEX System.  Thomson MICROMEDEX, Greenwood Village, Colorado.

6.      Eriksson BI, Eriksson E. Impaired fibrino-lysis and postoperative thrombembolism in orthopedic patients.

7.      CID and LOZANO. Transfusion 2005;45;1307-07

8.      BEKASSY Z,ASTEDT B Treatment with fibrinolytic inhibitor tranexamic acid gynecol scand 1990;69;353-54

9.      PIER MANNUCCIO and MARCEL LEVI. Prevention and treatment of major blood loss.N Eng J Med 2007;356;2301-11.

10.  Benoni G, Lethagen S, Fredin H.  The effect of tranexamic acid on local and plasma fibrinolysis during total knee arthoplasty.  Thrombosis research 1997;85 (3):195-206.

11.  Sulco,adams gl et al. global blood management in orthopedic surgery

12.  Lissa hall Zimmerman causes and consequences of critical bleeding and mech; of blood coagulation.

13.  Eriksson BI, Eriksson E. Impaired fibrinolysis and postoperative thrombemb-olism in orthopedic patients.

Corresponding Author

Dr Sobha S

Additional Professor, Dept of Anesthesiology

Government Medical College, Thiruvananthapuram